

PROGENICS PHARMACEUTICALS INC  
Form 8-K  
March 04, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The**  
**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): March 4, 2014**

**Progenics Pharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**777 Old Saw Mill River Road, Tarrytown, New York**

**000-23143**  
**(Commission**

**File Number)**

**13-3379479**  
**(IRS Employer**

**Identification No.)**

**10591**

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (914) 789-2800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today sold 1,141,304 additional primary shares of its common stock at a public offering price of \$4.60 per share pursuant to the exercise in full of the over-allotment option granted to the underwriters in the Company's February 26th public offering of 7,608,696 common shares. Net proceeds from the exercise were approximately \$4.9 million, after deducting underwriting discounts and commissions. Jefferies LLC acted as sole book-running manager and as representative of co-managers Needham & Company, LLC and Brean Capital, LLC. The offering was made under the Company's \$150 million shelf registration statement, including a February 21st prospectus supplement.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROGENICS PHARMACEUTICALS,  
INC.**

**By: /s/ ANGELO W. LOVALLO, JR.  
Angelo W. Lovallo, Jr.  
Vice President, Finance & Treasurer  
(Principal Financial and Accounting  
Officer)**

Date: March 4, 2014